{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:54:23Z","timestamp":1790873663205,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ANR","award":["ANR-21-CE17-0025 JDMINF2"],"award-info":[{"award-number":["ANR-21-CE17-0025 JDMINF2"]}]},{"name":"DMU MEFADO D\u00e9partement M\u00e9dico-Universitaire M\u00e9decine de l\u2019enfant et de l\u2019adolescent Necker Hospital Enfants-Malades, AP-HP, Paris, France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to establish the role of myositis-specific antibodies (MSAs) in the association between type I interferon (IFN-I) plasma levels and disease activity in juvenile dermatomyositis (JDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively obtained 400 samples from 101 JDM patients from two independent cohorts. Autoantibody levels were determined for all patients. Muscle activity was assessed using the Childhood-Myositis Assessment Scale (CMAS). Two characterized homebrew digital ELISAs measuring, respectively, all 12 IFN-\u03b1 subtype protein and IFN-\u03b2 were used to quantify IFN-I in patient plasma. Receiver operating characteristic (ROC) curve analysis was used to identify IFN-I thresholds associated with CMAS changes. Correlations between IFN-I levels and CMAS were assessed at recruitment using Spearman\u2019s test, and longitudinally using mixed-effects models to account for repeated measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IFN-\u03b1 levels were higher in melanoma differentiation-associated gene 5 (MDA5)-positive patients while IFN-\u03b2 levels were comparable across MSA subgroups. IFN-\u03b2 was found to be more effective than IFN-\u03b1 in distinguishing between active and inactive muscle disease, and between severe and non-severe disease status. Over the disease course, we identified IFN-\u03b2 as a reliable biomarker of muscle disease activity regardless of MSA expression. In contrast, IFN-\u03b1 levels showed a specific association with CMAS only in MDA5-positive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The exclusive association of IFN-\u03b1 levels with muscle clinical score in anti-MDA5-positive patients suggests a subgroup-specific pathophysiological mechanism. These findings underscore potentially distinct roles for IFN-I subtypes (IFN-\u03b1 and IFN-\u03b2) as circulating biomarkers of muscle disease activity in JDM according to MSA expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf549","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:48:41Z","timestamp":1760618921000},"source":"Crossref","is-referenced-by-count":5,"title":["IFN-\u03b1 levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2965-0400","authenticated-orcid":false,"given":"Thomas R J","family":"Moreau","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques UMR8601 , Paris,","place":["France"]},{"name":"Translational Immunology Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bondet","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia R","family":"Veldkamp","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Centre Utrecht, Utrecht University , Utrecht,","place":["The Netherlands"]},{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2496-6989","authenticated-orcid":false,"given":"Diego","family":"Bletry","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques UMR8601 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Ramos","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Villain","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-9640","authenticated-orcid":false,"given":"Na\u00efm","family":"Ouldali","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alexandra","family":"Alyanakan","sequence":"additional","affiliation":[{"name":"Department of Biological Immunology, Necker-Enfants Malades Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker-Enfants Malades Hospital (AP-HP5, Imagine Institute, INSERM) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bonhomme","sequence":"additional","affiliation":[{"name":"CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques UMR8601 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-7455","authenticated-orcid":false,"given":"Glory","family":"Dingulu","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dumaine","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc-Bao","family":"Duong","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Charuel","sequence":"additional","affiliation":[{"name":"Department of Immunology, Sorbonne Universit\u00e9, La Piti\u00e9-Salp\u00eatri\u00e8re Hospital (AP-HP) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurye-Anne","family":"Eveillard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fournier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2798-9141","authenticated-orcid":false,"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]},{"name":"Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, INSERM U1163 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Isapof","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Maladies Neuromusculaires Nord\/Est\/Ile de France, Service de Neurop\u00e9diatrie, H\u00f4pital Trousseau , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vinit","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Welfringer-Morin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker-Enfants Malades Hospital (AP-HP5, Imagine Institute, INSERM) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"van Royen-Kerkhof","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Centre Utrecht, Utrecht University , Utrecht,","place":["The Netherlands"]},{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Gitiaux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques UMR8601 , Paris,","place":["France"]},{"name":"Department of Paediatric Neurophysiology, Reference Center for Neuromuscular Diseases AP-HP, Necker-Enfants Malades Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-333X","authenticated-orcid":false,"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"General Paediatrics, Infectious Disease and Internal Medicine Department, Robert Debr\u00e9 Hospital, AP-HP , Paris,","place":["France"]},{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Department of General Pediatrics, Trousseau Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2308","authenticated-orcid":false,"given":"Darragh","family":"Duffy","sequence":"additional","affiliation":[{"name":"Translational Immunology Unit, Institut Pasteur, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[{"name":"Reference centre for inflammatory rheumatism, AutoImmune disease and Systemic interferonopathies in childrEn (RAISE) , Paris,","place":["France"]},{"name":"Paediatric Haematology-Immunology and Rheumatology Department, Necker-Enfants Malades Hospital, AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-0187","authenticated-orcid":false,"given":"Mathieu P","family":"Rodero","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]},{"name":"CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques UMR8601 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Dutch Juvenile Myositis Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia S M","family":"Kamphuis Rotterdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther P A H","family":"Hoppenreijs Nijmegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wineke","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Merlijn","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra C E","family":"Hissink Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026020205392478100_keaf549-B1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205392478100_keaf549-B2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2026020205392478100_keaf549-B3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026020205392478100_keaf549-B4","doi-asserted-by":"crossref","first-page":"e2250307","DOI":"10.1002\/eji.202250307","article-title":"Heterogeneity and functions of the 13 IFN-\u03b1 subtypes\u2014lucky for some?","volume":"53","author":"Moreau","year":"2023","journal-title":"Eur J Immunol"},{"key":"2026020205392478100_keaf549-B5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.41625","article-title":"From diagnosis to prognosis: revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies","volume":"73","author":"Hou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/art.41615","article-title":"Comparison of lesional juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology","volume":"73","author":"Turnier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B8","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026020205392478100_keaf549-B9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B10","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"key":"2026020205392478100_keaf549-B11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"2026020205392478100_keaf549-B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/art.41096","article-title":"Circulating interferon-\u03b1 measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity: comment on the article by Mathian et al","volume":"72","author":"Melki","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/ard.2010.139949","article-title":"Interferon \u03b2 is associated with type 1 interferon-inducible gene expression in dermatomyositis","volume":"70","author":"Liao","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020205392478100_keaf549-B14","doi-asserted-by":"crossref","first-page":"1529582","DOI":"10.3389\/fimmu.2025.1529582","article-title":"Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis","volume":"16","author":"Bolko","year":"2025","journal-title":"Front Immunol"},{"key":"2026020205392478100_keaf549-B15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026020205392478100_keaf549-B16","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3389\/fimmu.2018.02951","article-title":"Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools","volume":"9","author":"Wienke","year":"2018","journal-title":"Front Immunol"},{"key":"2026020205392478100_keaf549-B17","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.3390\/diagnostics11122246","article-title":"Profiling of myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies","volume":"11","author":"Mahler","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026020205392478100_keaf549-B18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpeds.2017.12.053","article-title":"Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity","volume":"195","author":"Pachman","year":"2018","journal-title":"J Pediatr"},{"key":"2026020205392478100_keaf549-B19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2026020205392478100_keaf549-B20","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1093\/rheumatology\/kead165","article-title":"In-depth proteomic analysis of juvenile dermatomyositis serum reveals protein expression associated with muscle-specific autoantibodies","volume":"62","author":"Sato","year":"2023","journal-title":"Rheumatology"},{"key":"2026020205392478100_keaf549-B21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205392478100_keaf549-B22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord NMD"},{"key":"2026020205392478100_keaf549-B23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fcimb.2019.00296","article-title":"Plasma type I IFN protein concentrations in human tuberculosis","volume":"9","author":"Llibre","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2026020205392478100_keaf549-B24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.20179","article-title":"Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies","volume":"50","author":"Huber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026020205392478100_keaf549-B25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026020205392478100_keaf549-B26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020205392478100_keaf549-B27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","article-title":"Repeated measures correlation","volume":"8","author":"Bakdash","year":"2017","journal-title":"Front Psychol"},{"key":"2026020205392478100_keaf549-B28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2024","journal-title":"Rheumatology"},{"key":"2026020205392478100_keaf549-B29","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/rheumatology\/kez525","article-title":"Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-\u03b1 signalling","volume":"59","author":"Melki","year":"2020","journal-title":"Rheumatology"},{"key":"2026020205392478100_keaf549-B30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2026020205392478100_keaf549-B31","doi-asserted-by":"crossref","first-page":"1249844","DOI":"10.3389\/fimmu.2023.1249844","article-title":"Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2026020205392478100_keaf549-B32","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026020205392478100_keaf549-B33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cytogfr.2009.07.005","article-title":"The role of differential expression of human interferon\u2014a genes in antiviral immunity","volume":"20","author":"G\u00e9nin","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026020205392478100_keaf549-B34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol Rev"},{"key":"2026020205392478100_keaf549-B35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J Neurol"},{"key":"2026020205392478100_keaf549-B36","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"key":"2026020205392478100_keaf549-B37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026020205392478100_keaf549-B38","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"2026020205392478100_keaf549-B39","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","article-title":"Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains","volume":"63","author":"Van Gompel","year":"2024","journal-title":"Rheumatology"},{"key":"2026020205392478100_keaf549-B40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/annrheumdis-2023-eular.3230","article-title":"Pos1207 efficacy and safety of anti-Ifn\u03b2-specific monoclonal antibody, Pf-06823859, on myositis: phase 2 study in patients with moderate-to-severe dermatomyositis","volume":"82","author":"Aggarwal","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026020205392478100_keaf549-B41","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf549\/64739220\/keaf549.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf549\/64739220\/keaf549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf549\/64739220\/keaf549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:39:34Z","timestamp":1770028774000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf549\/8292704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf549","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,17]]},"article-number":"keaf549"}}